ROVI acquires Falithrom® for the German market

ROVI will pay Hexal nine million euros for the product, the net sales of which totalled close to 3.5 million euros in 2017


Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has announced the purchase of Falithrom®, which was owned by Hexal AG (“Hexal”), a company belonging to the Sandoz division of Novartis, to be directly marketed by ROVI in Germany.

Falithrom® is used for the prevention and treatment of thromboembolic disease including venous thrombosis, thromboembolism, and pulmonary embolism as well as for the prevention of ischemic stroke in patients with atrial fibrillation (AF).

According to IQVIA, the 2017 net sales of the product in Germany totalled around 3.5 million euros. ROVI will pay Hexal nine million euros for the product.

Under this agreement, Falithrom® will be directly marketed by ROVI in Germany as soon as the administrative processes to authorize the transfer of the marketing authorization are completed before the German Federal Institute for Drugs and Medical Devices (BfArM).

Juan López-Belmonte Encina, ROVI’s CEO, commented: “With Falithrom®, ROVI reinforces its position in the anticoagulant market in Germany, the largest market in Europe, as part of its strategy to become a European player. Likewise, Falithrom® fully complements our existing portfolio and will be immediately accretive to our Germany subsidiary’s earnings”.

No votes yet
 
Related
Laboratorios Farmacéuticos ROVI, S.A. (ROVI) informs on the evaluation process to obtain marketing authorisation for Risvan® (Risperidone...
2 min
16/02/2023
Madrid, 6th February, 2023 This Monday, the Romanian Minister of Health, Alexandru Rafila, visited the ROVI plant in Alcalá de Henares....
2 min
06/02/2023
Madrid: 28 of December 2022 The project entitled “Bioreactors and Biostains with Heparin for the Regeneration of Elastic Tissues (...
1 min
28/12/2022